Research in Social and Administrative Pharmacy
Volume 6, Issue 3 , Pages 246-256 , September 2010

Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: A microcosting study

  • Dong-Churl Suh, M.B.A., Ph.D.

      Affiliations

    • Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020, USA
    • The Cancer Institute of New Jersey, New Brunswick, NJ, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 732 445 5215x402; fax: +1 732 445 2533.
    • ,
  • Christopher A. Powers, Pharm.D.

      Affiliations

    • U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, Baltimore, MD 21244, USA
    • Dr Christopher A. Powers participated in this study while he was in health economics and outcomes research fellowship program.
    • ,
  • Joseph A. Barone, Pharm.D.

      Affiliations

    • Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020, USA
    • ,
  • HyunChul Shin, Ph.D.

      Affiliations

    • Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020, USA
    • Korea Health Insurance Review Agency, Seoul, 137-927 South Korea
    • ,
  • Jinweon Kwon, Ph.D.

      Affiliations

    • Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020, USA
    • ,
  • Susan Goodin, Pharm.D.

      Affiliations

    • Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020, USA
    • The Cancer Institute of New Jersey, New Brunswick, NJ, USA
    • Division of Medical Oncology, Department of Medicine, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA

References 

  1. Centers for Disease Control and Prevention. Health, United States, 2006 With Chartbook on Trends in the Health of Americans. Hyattsville, MD 2006.
  2. American Cancer Society . Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 2007;
  3. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol. 2004;22:2214–2232
  4. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med. 1994;330(16):1136–1142
  5. Thomas CT, Ammar A, Farrell JJ, Elsaleh H. Radiation modifiers: treatment overview and future investigations. Hematol Oncol Clin North Am. 2006;20:119–139
  6. Sato Y, Takayama T, Sagawa T, Okamoto T, Miyanishi K, Sato T. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. Cancer Chemother Pharmacol. 2006;58:570–576
  7. Schmidt J, Patrut EM, Ma J, Jager D, Knaebel H-P, Buchler MW. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma. Cancer Immunol Immunother. 2006;55:1396–1405
  8. Le Q-T, Taira A, Budenz S, et al. Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable state IV head and neck squamous cell carcinomas. Cancer. 2006;106:1940–1949
  9. Fiore FD, Lecleire S, Rigal O, et al. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol. 2006;12(26):4185–4190
  10. Kerr D, O'Connor K. The costs of managing advanced colorectal cancer: a broad perspective. Anticancer Drugs. 1997;8:S23–S26
  11. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol. 1998;16(7):2557–2567
  12. Lokich JJ, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors—Part one. Model projections for cost based on charges. Cancer. 1996;78:294–299
  13. Ron IG, Lotan A, Inbar MJ, Chaitchik S. Advanced colorectal carcinoma: redefining the role of oral ftorafur. Anticancer Drugs. 1996;7:649–654
  14. Ross P, Heron J, Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer. 1996;32A(Suppl 5):S13–S17
  15. Niebel BW, Freivalds A. Methods, Standards, and Work Design. 11th ed.. Burr Ridge, IL: McGraw-Hill; 2002;
  16. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed.. New York, NY: Oxford University Press; 1997;
  17. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996;
  18. United States Department of Health & Human Services . Determining the Unit Cost of Services. Washington, DC: Public Health Service; 1990;
  19. Deakin EB, Maher MW. Cost Accounting. 3rd ed.. New York, NY: McGraw-Hill; 1991;Professional Publishing
  20. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Boca Raton, FL: Chapman & Hall/CRC; 1993;
  21. Consumer price indexes. Available at: http://www.bls.gov/cpi/2006;Accessed 03.10.06
  22. SAS Institute Inc . SAS/STAT User's Guide, Version 8. Cary, NC: SAS Institute; 1999;
  23. Schrag D. The price tag on progress—chemotherapy for colorectal cancer. N Engl J Med. 2004;351(4):317–319
  24. Medicare Payment Advisory Commission . Payment for Pharmacy Handling Costs in Hospital Outpatient Departments. Issues in a Modernized Medicare Program. Washington, DC: Medicare Payment Advisory Commission; 2005;137–155
  25. American Society of Clinical Oncology . CMS Releases Proposed Medicare Payment Regulations for 2007. Available at: 2006;http://www.asco.org/portal/site/ASCOAccessed 07.09.06
  26. Center for Medicare and Medicaid Services . Hospital Outpatient PPS. Available at: 2006;http://www.cms.hhs.gov/HospitalOutpatientPPS/01_overview.aspAccessed 06.09.06
  27. U.S. Pharmacopeia . USP <797>Guidebook to Proposed Revisions Pharmaceutical Compounding—Sterile Preparations Product Information. Available at: http://www.usp.org/USPNF/pf/generalChapter797.htmlAccessed 03.10.06
  28. Maroun JA, Asche C, Romeyer F, et al. A cost comparison of oral tegafur plus uracil/folic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics. 2003;21(14):1039–1051
  29. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomics analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer. 2006;94:1122–1129
  30. Castel LD, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer. 2001;9:545–551
  31. Dranove D. Measuring costs. In:  Sloan FA editors. Valuing Health Care. New York, NY: Cambridge University Press; 1995;
  32. Barnes RM. Motion and Time Study: Design and Measurement of Work. 7th ed.. New York, NY: John Wiley & Sons; 1980;
  33. Ruchlin HS, Elkin EB, MacKenzie CR, Williams-Russo P, Allegrante JP. Determining the cost of a clinical intervention through the use of shadow pricing. Arthritis Care Res. 1997;10(5):343–351
  34. Bailes JS. Payment and coverage issues affecting medical oncology. Breast Cancer Res Treat. 1993;25:119–126
  35. Cowan DH. The effect of Medicare reimbursement policies on the cost and setting of cancer chemotherapy. Cancer Invest. 1996;14(2):184–186
  36. Scuplher M, Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy. Pharmacoeconomics. 2000;17(4):361–370
  37. Jansman FG, Postman MJ, van Hartskamp D, Willemse PH, Brouwers JR. Cost benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther. 2004;26(4):579–589
  38. Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J Manag Care Pharm. 2006;12(7):570–577
  39. Burke TA, McKee JR, Wilson HC, Donahue RMJ, Batenhorst AS, Pathak DS. A comparison of time and motion and self-reporting methods of work measurement. J Nurs Adm. 2000;30(3):118–125

PII: S1551-7411(09)00080-1

doi: 10.1016/j.sapharm.2009.07.004

Research in Social and Administrative Pharmacy
Volume 6, Issue 3 , Pages 246-256 , September 2010

Article Tools

* Image Usage & Resolution